HAMAM

Despite tremendous advances in modern imaging technology, both early detection and accurate diagnosis of breast cancer are still unresolved challenges. Today, a variety of imaging modalities and image-guided biopsy procedures exist to identify and characterize morphology and function of suspicious breast tissue. However, a clinically feasible solution for breast imaging, which is both highly sensitive and specific with respect to breast cancer, is still missing. As a consequence, unnecessary biopsies are taken and tumours frequently go undetected until a stage where therapy is costly or unsuccessful.

HAMAM (Highly accurate breast cancer diagnosis through integration of biological knowledge, novel imaging modalities, and modelling) project will tackle this challenge by providing a means to seamlessly integrate the available multi-modal images and the patient information on a single clinical workstation. Based on knowledge gained from a large multi-disciplinary database, populated within the scope of this project, suspicious breast tissue will be characterised and classified.

HAMAM will achieve this by:

  • Building the tools needed to integrate datasets / modalities into a single interface.
  • Providing pre processing / standardization tools that will allow for optimal comparison of disparate data
  • Building spatial correlation information datasets to allow for new similarity and multimodal tissue models. These will be key in the detection and diagnosis of breast cancer
  • Building in adaptability that allows for the integration of other sources of knowledge such as tumour models, genetic data, genotype, phenotype and standardised imaging.

The exact diagnosis of suspicious breast tissue is ambiguous in many cases. HAMAM will resolve this using the statistical knowledge extracted from the large case database. The clinical workstation will suggest additional image modalities that may be captured to optimally resolve these uncertainties. The workstation thus guides the clinician in establishing a patient specific optimal diagnosis. This ultimately leads to a more specific and individual diagnosis.

For further information, please visit:
http://www.hamam-project.eu

Project co-ordinator:
EIBIR gemeinnuetzige GmbH zur Foerderung der. Erforschung der biomedizinischen Bildgebung

Partners:

  • Boca Raton Community Hospital Inc (USA)
  • MeVis Research GmbH (Germany)
  • MeVis Medical Solutions AG (Germany)
  • University College London (United Kingdom)
  • Radboud Universiteit Nijmegen - Stichting Katholieke Universiteit (Netherlands)
  • Charité - Universitätsmedizin Berlin (Germany)
  • The University of Dundee (United Kingdom)
  • Eidgenössische Technische Hochschule Zürich (Switzerland)

Timetable: from 09/2008 - to 08/2011

Total cost: € 4.250.000

EC funding: € 3.100.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

First Virtual DMEA to Open with a Wide R…

16 - 18 June 2020, Berlin, Germany. Under the heading 'DMEA sparks' and taking place for the first time, this year's DMEA is an entirely virtual event. From 16 to 18...

Philips Launches HealthSuite Clinical Tr…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced Clinical Trial Accelerator on Philips HealthSuite. This new tailored set of capabilities allows life science organizations to...

New AI Diagnostic can Predict COVID-19 w…

Researchers at King's College London, Massachusetts General Hospital and health science company ZOE have developed an artificial intelligence diagnostic that can predict whether someone is likely to have COVID-19 based...

Biomax Provides AI-Based Semantic Search…

The bioinformatics company Biomax, headquartered in Planegg, Germany, makesitssemantic search platform AILANI available free of charge to research institutes around the world in order to support the rapid and successful...

COVID-19 and Health Tech: Building on th…

Highland Marketing's advisory board met to discuss the health tech response to the coronavirus outbreak. In many areas, this has been hugely impressive: but there are gaps, and there will...

InsurTech Hub Munich and dmac/Digital He…

InsurTech Hub Munich (ITHM) and dmac - Medical Valley Digital Health Application Center part of the Digital Health Hub Nuremberg/Erlangen announce a new cross-industry accelerator for the second half of...

Viveo Health Offers Free Telemedicine So…

Viveo Health, a global e-Health innovator, is making its 'Virtual Office for Doctors' platform free of charge to doctors and other medical professionals worldwide in light of the surge in...

The Dedalus Group, Participated by Ardia…

The Dedalus Group, a leading European company, and one of the worldwide main ones, active in clinical healthcare information systems to support clinical professionals and organizations in order to improve...

Supercomputer Simulations Present Potent…

Several drugs approved for treating hepatitis C viral infection were identified as potential candidates against COVID-19, a new disease caused by the SARS-CoV-2 coronavirus. This is the result of research...

The COVID-19 pandemic reveals the potent…

Two new articles provide insights on the use of telehealth or virtual care in the age of COVID-19 and beyond, pointing to its value to not only prevent contagious diseases...

WiFi SPARK Works with Visionable to Conn…

Seven NHS Trusts are using technology developed by WiFi SPARK in response to an urgent request from leading NHS Trusts to find a way to connect hospital patients with their...

Digital Contact Tracing for COVID-19: An…

An article in CMAJ (Canadian Medical Association Journal) analyzes the strengths and limitations of digital contact tracing for people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to help...